We are diamond seekers among new therapies
We offer cooperation to people of science who have already carried out their research projects aimed at creating a new drug to the point where the original idea has been verified in laboratory conditions and animal studies, and you can start preparing for the last two steps - says Adam Kruszewski, MD, CEO of Orphinic Scientific in an interview by Krzysztof Jakubiak, editor-in-chief of mZdrowie.pl.
It is about clinical trials that require completely different competences and negotiations with large pharmaceutical companies, where experience and business knowledge count. We help to perform clinical tests and bring a new drug or medical device to registration. In addition to using our know-how, we co-finance projects by taking shares in them.
Invest in therapy by Gazeta Wyborcza
In Poland, they know all the biotechnology companies that are trying to introduce new therapies, and these companies also know Orphinic Scientific - writes Witold Gadmski in Gazeta Wyborcza, Poland's leading newspaper. In our part of the continent think tank Central & East European Health Policy Network, co-founded by Dr. Adam Kruszewski, helps in finding interesting projects. Orphinic Scientific also has contacts with leading world universities, where the company's scouts observe the most interesting projects. The company is also developing an artificial intelligence tool that allows it to search for various projects in the world that are mature enough, but venture capital funds have not yet entered them.
READ THE ARTICLE ONLINE
#biotech #pharma#lifescience#biotechnology
Orphinic Scientific portfolio model
Until recently, biotech companies tended to be founded with a focus on a single technology or biological pathway.… Over the past five years, however, an innovative business model has emerged for biotech. In it, a portfolio manager controls a set of companies spanning multiple technologies and disease areas. Instead of focusing on a single technology or in the traditional way, the portfolio manager uses a distinctive form of expertise—such as in fundraising, investment, venture creation, R&D, manufacturing, commercial management, leadership, and broad credibility—to start a suite of subsidiaries, each dedicated to an individual drug program.
In the latest article by Mckinsey & Company A new portfolio model for biotech, the new model is analyzed in terms of its opportunities for the biopharmaceutical industry.
